1,721,053 research outputs found
WSO895703 Supplemental material - Supplemental material for Hematoma Hounsfield units and expansion of intracerebral hemorrhage: A potential marker of hemostatic clot contraction
No full textSupplemental material, WSO895703 Supplemental material for Hematoma Hounsfield units and expansion of intracerebral hemorrhage: A potential marker of hemostatic clot contraction by Han-Gil Jeong, Jae Seung Bang, Beom Joon Kim, Hee-Joon Bae and Moon-Ku Han in International Journal of Stroke</p
WSO884517 Supplemental Material - Supplemental material for Characteristics and management of stroke in Korea: 2014–2018 data from Korean Stroke Registry
No full textSupplemental material, WSO884517 Supplemental Material for Characteristics and management of stroke in Korea: 2014–2018 data from Korean Stroke Registry by Han-Yeong Jeong, Keun-Hwa Jung, Heejung Mo, Chan-Hyuk Lee, Tae Jung Kim, Jong-Moo Park, MiSun Oh, Ji Sung Lee, Beom Joon Kim, Joon-Tae Kim, Jinkwon Kim, Woo-Keun Seo, Jun Lee, Jae-Kwan Cha, Sang-Bae Ko, Hee-Joon Bae and Byung-Woo Yoon in International Journal of Stroke</p
Supplementary Tables -Supplemental material for Procedural and clinical outcomes of endovascular recanalization therapy in patients with cancer-related stroke
No full textSupplemental material, Supplementary Tables for Procedural and clinical outcomes of endovascular recanalization therapy in patients with cancer-related stroke by Seunguk Jung, Cheolkyu Jung, Jae Hyoung Kim, Byung Se Choi, Yun Jung Bae, Leonard Sunwoo, Ho Geol Woo, Jun Young Chang, Beom Joon Kim, Moon-Ku Han and Hee-Joon Bae in Interventional Neuroradiology</p
Incidence of neutropenia in patients with ticlopidine/Ginkgo biloba extract combination drug for vascular events: A post-marketing cohort study
No full textBackground and purposeThe ticlopidine/Ginkgo biloba ext. combination drug (Yuclid) is used as an antiplatelet agent for prevention of vascular events since its approval in 2008. The purpose of this study is to explore the safety of ticlopidine/Ginkgo biloba combination, mainly regarding the incidence of neutropenia, through a post-marketing surveillance study.MethodsFrom March 2009 to October 2015, a total of 4839 subjects had been enrolled in this study. The enrollments were conducted by 152 doctors of 89 hospitals according to the regulations for post-marketing surveillance programs in Korea. If a subject was administered the drug once, he/she was included in the safety analysis set for any adverse events and bleedings, and the primary safety evaluation regarding neutropenia was conducted in subjects who completed 3-month blood test follow-up. We predefined that 1% reduction in neutropenia incidence by ticlopidine/Ginkgo biloba ext. combination from the previously reported incidence of ticlopidine of 2.3% was clinically meaningful.ResultsAmong the safety analysis set of 4831 patients (99.8% of the enrolled subjects), 3150 (65.1%) completed evaluation for neutropenia at 3 months which is the primary safety endpoint. The major causes of dropout were no follow-up visit at 3 months (n = 1016) and violation of the follow-up period (n = 503). Nine patients experienced neutropenia (Absolute neutrophil count [ANC] ≤ 1200mm3) and the estimated cumulative incidence at 3 months is 0.29% (95% confidence interval, 0.13%– 0.54%). Severe neutropenia (ANC ≤ 450mm3) did not occur in any patients.ConclusionsThe incidence of neutropenia with addition of Ginkgo biloba ext. to ticlopidine may be lower than the previously reported incidence of neutropenia with ticlopidine, which needs to be confirmed in randomized controlled trials.</div
Supplemental material for Who will benefit more from low-dose alteplase in acute ischemic stroke?
No full textSupplemental Material for Who will benefit more from low-dose alteplase in acute ischemic stroke? by Xia Wang, Keon-Joo Lee, Tom J Moullaali, Beom Joon Kim, Qiang Li, Hee-Joon Bae, Cheryl Carcel, Candice Delcourt, Hisatomi Arima, Shoichiro Sato, Thompson G Robinson, Lili Song, Guofang Chen, Jie Yang, John Chalmers, Craig S Anderson, Richard Lindley, Mark Woodward and for the ENCHANTED Investigators in International Journal of Stroke</p
Cardioembolism and Involvement of the Insular Cortex in Patients with Ischemic Stroke.
No full textTo evaluate whether topographical characteristics of insular involvement in ischemic stroke are associated with cardioembolism.A consecutive series of patients hospitalized for ischemic stroke within 7 days of symptom onset were identified. Based on diffusion-weighted imaging, we included those who had ischemic lesions in the middle cerebral artery (MCA) territory. Each patient was assigned to one of two groups based on the presence or absence of insular involvement. The primary outcome was the frequency of cardioembolism, which was compared based on insular involvement. Of 1,311 patients with ischemic stroke in the MCA territory, 112 had insular involvement (8.5%). The frequency of cardioembolism in patients with insular involvement (52.7%) was significantly higher than that in patients without insular involvement (30.4%, P < 0.001). Although insular involvement was associated with a severe baseline National Institutes of Health Stroke Scale score (13 vs. 4), it did not independently affect the 3-month functional outcome.In cases of stroke in the MCA territory, involvement of the insular cortex may be associated with a risk of cardioembolism
Remote blood pressure monitoring and behavioral intensification for stroke: A randomized controlled feasibility trial
No full textMeasuring blood pressure (BP) at home and remote monitoring can improve the patient’s adherence to BP control and vascular outcomes. This study evaluated the feasibility of a trial regarding the effects of an intensive mobile BP management strategy versus usual care in acute ischemic stroke patients. A feasibility-testing, randomized, open-labeled controlled trial was conducted. Remote BP measurement, data transmission, storage, and centralized monitoring system were organized through a Bluetooth-equipped sphygmomanometer paired to the participants’ smartphones. Participants were randomized equally into intensive management (behavioral intensification to measure BP at home by texting, direct telephone call, or breakthrough visit) and control (usual care) groups. The primary feasibility outcomes were: 1) recruitment time for the pre-specified number of participants, 2) retention of participants, 3) frequency of breakthrough visit calls, 4) response to breakthrough visit call, and 5) proportions satisfying BP measurement criteria. Sixty participants were randomly assigned to the intensive management (n = 31) and control (n = 29) groups, of which 57 participants were included in the primary analysis with comparable baseline characteristics. Recruitment time from the first to the last participant was 350 days, and 95% of randomized participants completed the final visit (intensive, 94%; control, 98%). Eight breakthrough visit calls were made to 7 participants (23%), with complete and immediate responses within 3 ± 4 days. The median of half-day blocks fulfilling the BP measurement criteria per patient were 91% in the intensive group and 83% in the control group (difference, 12.2; 95% confidence interval, 2.2–22.2). No adverse events related to the trial procedures were reported. The intensive monitoring, including remote BP measurement, data transfer, and centralized monitoring system, engaged with behavioral intensification was feasible if the patients complied with the intervention. However, the device utilized would need further improvement prior to a large trial.</div
Supplemental material for Quality of acute stroke care in Korea (2008–2014): Retrospective analysis of the nationwide and nonselective data for quality of acute stroke care
No full textSupplemental Material for Quality of acute stroke care in Korea (2008–2014): Retrospective analysis of the nationwide and nonselective data for quality of acute stroke care by Hong-Kyun Park, Seong-Eun Kim, Yong-Jin Cho, Jun Yup Kim, Hyunji Oh, Beom Joon Kim, Jihoon Kang, Keon-Joo Lee, Min Uk Jang, Jong-Moo Park, Kwang-Yeol Park, Kyung Bok Lee, Soo Joo Lee, Ji Sung Lee, Juneyoung Lee, Ki Hwa Yang, Ah Rum Choi, Mi Yeon Kang, Eric E Smith, Philip B Gorelick and Hee-Joon Bae in European Stroke Journal</p
Supplemental material for Low-dose versus standard-dose alteplase in acute ischemic stroke in Asian stroke registries: an individual patient data pooling study
No full textSupplemental Material for Low-dose versus standard-dose alteplase in acute ischemic stroke in Asian stroke registries: an individual patient data pooling study by Xia Wang, Jingwei Li, Tom J Moullaali, Keon-Joo Lee, Beom Joon Kim, Hee-Joon Bae, Anxin Wang, Yilong Wang, David Z Wang, Yongjun Wang, Masaya Kumamoto, Kazunori Toyoda, Masatoshi Koga, Shoichiro Sato, Sohei Yoshimura, Yi Sui, Bing Xu, Ying Xiao, Tsong-Hai Lee, Chia-Wei Liou, Jiann-Der Lee, Tsung-I Peng, Yen-Chu Huang, Prakash R Paliwal, Manasi Sharma, Cyrus Escabillas, Jose C Navarro, Mu-Chien Sun, Yi Dong, Qiang Dong, Craig S Anderson and Vijay K Sharma: for the ENCHANTED Investigators in International Journal of Stroke</p
Development of stroke identification algorithm for claims data using the multicenter stroke registry database
No full textBackgroundIdentifying acute ischemic stroke (AIS) among potential stroke cases is crucial for stroke research based on claims data. However, the accuracy of using the diagnostic codes of the International Classification of Diseases 10th revision was less than expected.MethodsFrom the National Health Insurance Service (NHIS) claims data, stroke cases admitted to the hospitals participating in the multicenter stroke registry (Clinical Research Collaboration for Stroke in Korea, CRCS-K) during the study period with principal or additional diagnosis codes of I60-I64 on the 10th revision of International Classification of Diseases were extracted. The datasets were randomly divided into development and validation sets with a ratio of 7:3. A stroke identification algorithm using the claims data was developed and validated through the linkage between the extracted datasets and the registry database.ResultsAltogether, 40,443 potential cases were extracted from the NHIS claims data, of which 31.7% were certified as AIS through linkage with the CRCS-K database. We selected 17 key identifiers from the claims data and developed 37 conditions through combinations of those key identifiers. The key identifiers comprised brain CT, MRI, use of tissue plasminogen activator, endovascular treatment, carotid endarterectomy or stenting, antithrombotics, anticoagulants, etc. The sensitivity, specificity, and diagnostic accuracy of the algorithm were 81.2%, 82.9%, and 82.4% in the development set, and 80.2%, 82.0%, and 81.4% in the validation set, respectively.ConclusionsOur stroke identification algorithm may be useful to grasp stroke burden in Korea. However, further efforts to refine the algorithm are necessary.</div
- …
